MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1517/14728214.13.2.323

Медицинская библиотека · Expert opinion on emerging drugs · 2008

Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma.

Kassam Shireen, Montoto Silvia

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

The incidence of non-Hodgkin's lymphoma, of which B-cell neoplasms are the commonest, has been increasing over the last 20 years. Treatment options have also increased, with improved response rates to first-line therapy. However, treatment failure with disease recurrence remains a major problem. Recently, the focus of drug development has shifted from conventional cytotoxic drugs to molecularly targeted agents and immunotherapy, driven by advances in the understanding of the molecular pathogenesis of these disorders.

OBJECTIVES

To review preclinical and clinical data on novel molecularly targeted therapies that show promise for the treatment of B-cell NHL.

METHODS

PubMed was used for literature searches and additional drug development data were provided by pharma projects.

RESULTS/

CONCLUSION

Large numbers of new drugs are at various stages of preclinical and clinical development. The challenge for the clinicians is how best to incorporate them into existing treatment regimes.

Для цитирования: Kassam Shireen, Montoto Silvia. Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma.. Expert opinion on emerging drugs. 2008. DOI: 10.1517/14728214.13.2.323.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.